CN Patent

CN111437386A — II型抗CD20抗体与选择性Bcl-2抑制剂的组合治疗

Assigned to Jiningte Co ltd · Expires 2020-07-24 · 6y expired

What this patent protects

本发明涉及II型抗CD20抗体与选择性Bcl‑2抑制剂的组合治疗。本发明涉及组合疗法，所述组合疗法涉及II型抗CD20抗体和选择性Bcl‑2抑制剂用于治疗患有癌症特别是表达CD20的癌症的患者。

USPTO Abstract

本发明涉及II型抗CD20抗体与选择性Bcl‑2抑制剂的组合治疗。本发明涉及组合疗法，所述组合疗法涉及II型抗CD20抗体和选择性Bcl‑2抑制剂用于治疗患有癌症特别是表达CD20的癌症的患者。

Drugs covered by this patent

Patent Metadata

Patent number
CN111437386A
Jurisdiction
CN
Classification
—
Expires
2020-07-24
Drug substance claim
No
Drug product claim
No
Assignee
Jiningte Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.